



HKTDC MEDICAL FAIR 2026 · FORUM STAGE

Clinical Intervention, re-imagined.

A robot that lets a clinician perform image-guided procedures from across the room — or across the city.

• INNOVATION REDEFINING PATIENT-CENTERED HEALTHCARE

MAY 11 · 11:40-12:10

Matthew Sefati
CEO, Cobionix Corporation

Booth 3E-D16
HKTDC Hong Kong Medical Fair

CODI® · 7 DOF · SMART HUB CART



THE COGNITIVE COBOT

**Hardware, software & clinical
workflow on one platform.**

THE BOTTLENECK

Every image-guided intervention still requires hands on the patient.

90%

of cardiac sonographers report work-related musculoskeletal injuries.

The same problem repeats across vascular access, ultrasound-guided injection, ablation, biopsy — the clinician's body is the bottleneck.

301.7M

ultrasound-guided procedures performed worldwide every year.

Hospitals can't hire their way out. Specialist scarcity, geographic concentration, and clinician injury all compound the same access problem.

AI software alone cannot solve a **physical** problem. The intervention layer needs hardware.

INTRODUCING CODI®

A cognitive cobot for clinical intervention.

Designed to perform — not just observe. A universal tool connector that accepts any market-cleared probe or instrument.

DEGREES OF FREEDOM

7

Collaborative robot arm.

WORK ACCURACY

0.2mm

Sub-millimeter probe placement.

MAXIMUM REACH

1.4m

Covers all patient sizes.

EMBEDDED SENSORS

150+

Force feedback & safety.

CODI® · FULL SYSTEM ON SMART HUB CART

UNIVERSAL CONNECTOR

Accepts any market-cleared probe or instrument — one platform, many interventions.



THE COGNITIVE COBOT

Hardware, software & clinical workflow on one platform.

The clinician stays in control. The robot does the reaching.

CLINICIAN · HAPTIC CONTROLLER

Diagnostic decisions stay with the human.

Real-time force, orientation and image come back through the haptic loop — minimal latency.

CODI® · PATIENT-SIDE

Sub-mm placement, repeatable every time.

Force, orientation and trajectory logged with the imaging stream — the procedure becomes data.




Same clinical workflow. Same diagnostic responsibility. Lower physical strain — and the option to extend reach via tele-intervention without re-training the team.

THREE INTERVENTION DOMAINS

Where CODI[®] is in clinical use today.

ACTIVE · UHS NHS



01 · DIAGNOSTIC ULTRASOUND

Cardiac & abdominal echo.

All four standard TTE views, repeatable across operators.
Sonographer training < 8 hrs.

IN DISCUSSION · LHSC




02 · IMAGE-GUIDED THERAPY

Vascular, EP, anaesthesia.

Pacemaker / defibrillator lead placement, vascular access,
regional anaesthesia — clinician-controlled.

TRIAL · USASK MULTI-SITE



03 · TELE-INTERVENTION

One expert, many sites.

Especially relevant for the Greater Bay Area — specialist
coverage extended without specialist travel.

ALREADY IN CLINICAL USE

Three live programs — UK, Canada, and growing.



University Hospital Southampton.

Active Ergo CODI® cardiac echo evaluation. All four standard TTE views achieved. Multi-site NHS expansion in motion.

COHORT TRAIN
n = 20 < 8 hrs

● Active clinical evaluation



University of Saskatchewan.

Multi-site tele-ultrasound trial, USask-funded. Data supports the Cobionix FDA 510(k) submission.

COHORT OUTPUT
70–90 510(k)

● Trial in progress



London Health Sciences Centre.

Discussion with the London Heart Rhythm Program for ultrasound-guided robotic procedures in pacemaker implantation research.

STAGE USE CASE
Scoping EP Lab

● Discussion in progress

HK is positioned as our Asia-Pacific gateway.

HK HOSPITAL REDEVELOPMENT

HK\$300B+

Investment in hospital redevelopment over the next decade — the largest single hospital capital cycle in the region’s history.

HKSTP SOFT LANDING

Cobionix is engaged with HKSTP — local infrastructure and clinical introductions are in motion.

01

World-class clinical community.

Hospital Authority sites · HKU and CUHK medical schools · strong cardiology and imaging faculties.

02

Common-Law IP protection.

Important for collaborations involving proprietary AI models and patented hardware.

03

Regulatory acceleration.

HK accepts FDA and CE / UKCA approvals as reference, accelerating future clinical translation.

04

Greater Bay Area gateway.

Research conducted in HK can scale into Mainland China via the GBA pilot pathway.

TALK TO US

Visit booth **3E-D16**. See CODI[®] up close.

STEP 01

Meet at our booth.

Stop by 3E-D16 to meet the team and walk through the platform with us in person.

STEP 02

Scoping conversation.

30 minutes with our clinical and product teams — bring your hardest intervention problem.

STEP 03

Luminary Program.

Early access · co-development · preferred terms for HK research and clinical partners.



Matthew Sefati · CEO, Cobionix Corporation

msefati@cobionix.com · cobionix.com · +1 647 495 6991

Booth 3E-D16
HKTDC HK Medical Fair